Skip to content

    Research Use Only

    This site is an independent educational resource for research compounds. We do not sell, distribute, or endorse human consumption of any compound. By entering, you confirm you are 21 years of age or older and agree to our Terms & Privacy Policy.

    🔬 100K+ researchers trust BodyHackGuide — Join r/BodyHackGuide
    NootropicsPreclinical

    Uridine Monophosphate (UMP) Dosage Guide: Protocols, Calculator & Safety

    Everything you need to know about Uridine Monophosphate (UMP) dosing — protocols, safety, and where to buy.

    Dosage Calculator

    Calculate exact dosing for Uridine Monophosphate (UMP).

    Dosing Protocols

    Beginner

    Starter protocol (first 4-6 weeks): 150-250 mg uridine monophosphate daily, with a choline source and optionally DHA.

    This protocol establishes the foundation of uridine-based membrane support nootropics and is suitable as a first experience for most users.

    Prerequisites:

    1. Confirm basic health status — no contraindications, no active pyrimidine antagonist chemotherapy, no severe hepatic or renal dysfunction.
    2. Consider whether your goals (general cognitive support, mood adjunct, membrane health) are appropriate for uridine — it is not a strong acute cognitive enhancer or antidepressant.
    3. Source from a reputable supplement vendor — look for uridine monophosphate disodium salt (UMP-Na2) with clear labeling, preferably with third-party testing.

    Dosing:

    • Uridine monophosphate 150-250 mg daily, taken with breakfast or the largest meal of the day.
    • Alpha-GPC 300 mg OR CDP-choline 250 mg daily, with the uridine.
    • DHA 700-1000 mg daily (from fish oil, krill oil, or algal oil), with a fat-containing meal for optimal absorption.
    • Sublingual uridine (150-250 mg): some users prefer sublingual administration for potentially better bioavailability. Dissolve under tongue for 1-2 minutes before swallowing residual.

    Duration and assessment:

    • Weeks 1-2: establish daily routine, track any side effects (mild GI upset, headache are possible), notice subtle changes in mood, energy, or cognition. Uridine effects are typically not acute — expect gradual rather than immediate changes.
    • Weeks 3-4: more reliable assessment of effects becomes possible. Compare to baseline.
    • Weeks 5-6: decision point — continue, adjust, or discontinue based on subjective benefit.

    What to expect:

    • Most users report subtle improvements in mood, mental clarity, and stress tolerance over 2-6 weeks of consistent dosing.
    • No acute "cognitive boost" — this is a membrane support supplement, not a stimulant.
    • Some users report more vivid dreams in the first few weeks.
    • Most users report no significant side effects.
    • A minority of users report no perceptible benefit — the subtle effect may not exceed their personal threshold for detection.

    Monitoring:

    • Daily subjective notes: mood, cognition, energy, sleep quality, any side effects.
    • Weekly review: trending positively, negatively, or neutral?
    • End-of-cycle (week 6): summary assessment — was this worthwhile?

    Stopping criteria:

    • Persistent GI symptoms or headache.
    • Significant mood deterioration.
    • Signs of gout flare (if predisposed).
    • No perceived benefit after 6 weeks — some users are non-responders.

    After the starter protocol:

    • If tolerated and beneficial: continue indefinitely at the starter dose, or progress to the intermediate protocol for higher doses and more complete stacking.
    • If ineffective: uridine may not be your compound; consider whether the stack (choline, DHA) without uridine provides benefit.

    Cost and practical considerations:

    • Uridine monophosphate is relatively inexpensive ($15-40 per month at typical doses).
    • Alpha-GPC or CDP-choline adds $10-30/month.
    • DHA/fish oil adds $10-30/month.
    • Full starter stack: approximately $40-100/month depending on brand and quality.
    Standard

    Intermediate protocol (users with confirmed tolerance and benefit on starter): 500-1000 mg/day uridine monophosphate, with full Mr. Happy stack components.

    This protocol is for users who have completed the starter protocol, confirmed tolerance and subjective benefit, and want to explore the full nootropic stack based on Wurtman group's mechanistic framework.

    Dosing:

    • Uridine monophosphate 500-1000 mg daily (split as 250-500 mg twice daily with breakfast and dinner/lunch).
    • Alpha-GPC 600 mg OR CDP-choline 500 mg daily, split with uridine doses.
    • DHA 1000-1400 mg daily (can split into morning and evening doses with fat-containing meals).
    • Optional additions:
      • Omega-3 EPA 500-1000 mg/day (often included in fish oil formulations with DHA).
      • B-complex vitamin providing modest doses of B1, B2, B3, B5, B6, B9, B12.
      • Vitamin D3 2000-5000 IU/day if not already supplemented.

    Specific nootropic stacking options (add one at a time, not all at once):

    • Noopept 10-20 mg/day for users seeking additional cognitive support.
    • Piracetam 1,600-4,800 mg/day for users preferring the racetam family.
    • Lions-mane 500-1000 mg/day for complementary neurotrophic support.
    • Sulbutiamine 200-400 mg/day for users with fatigue component.
    • Creatine monohydrate 3-5 g/day — cheap, safe, broadly beneficial including modest cognitive effects.

    Duration and cycling:

    • Uridine does not require cycling — it is a nutritional precursor rather than a psychoactive compound.
    • Most users dose continuously for months to years.
    • Periodic reassessment (every 3-6 months) is reasonable to verify continued benefit and check for any new medical factors.

    Monitoring:

    • Quarterly: subjective cognitive and mood assessment, comparison to baseline.
    • Annually: general health labs including CBC, CMP, lipid panel, HbA1c. If predisposed to gout, check uric acid.
    • If stacking multiple additional nootropics, more frequent assessment during stack changes.

    Advanced stacking considerations:

    Full "Mr. Happy+" stack (not endorsed, illustrative):

    • Uridine monophosphate 500-1000 mg/day
    • Alpha-GPC or CDP-choline 500-600 mg/day
    • DHA + EPA 1000-2000 mg/day
    • Noopept 20 mg/day
    • Lion's Mane 1000 mg/day
    • Creatine 5 g/day
    • Magnesium glycinate 200-400 mg/day
    • B-complex
    • Vitamin D3 3000-5000 IU
    • Comprehensive lifestyle (sleep, exercise, diet)

    This is an example of a "full spectrum" brain-health stack. Total cost approximately $80-150/month. Each component has independent evidence and mechanistic rationale; the combined effect is not additive in the sense of any component being curative, but the overall support for membrane health, mitochondrial function, energy metabolism, and neurotransmitter availability is reasonable.

    Red flags prompting reassessment:

    • New-onset significant side effects after dose increase.
    • Loss of previous benefits (though uridine tolerance development is unusual).
    • Cost escalation outpacing benefit.
    • Feeling of dependency on the stack (cognitive "crash" on missed doses).

    Long-term use considerations:

    • Uridine has been used in trials over 24+ months without safety signals.
    • Long-term use of uridine-choline-DHA stacks is a reasonable pattern for users seeking general brain-health support in midlife and beyond.
    • Periodic breaks are not required but are harmless if desired.
    Advanced

    Advanced protocol (experienced nootropic users, long-term brain-health focus): up to 1500-2000 mg/day uridine monophosphate with comprehensive supporting stack, integrated into a long-term cognitive preservation strategy.

    This protocol represents a maximal-support approach for users committed to long-term cognitive preservation strategies. It is for users with established tolerance and benefit from lower doses who want to maximise membrane-synthesis substrate availability.

    Dosing:

    • Uridine monophosphate 750-1000 mg twice daily (1500-2000 mg/day total), split with meals.
    • Alpha-GPC 900 mg/day OR CDP-choline 750 mg/day split across doses.
    • DHA 1400-2000 mg/day with EPA 500-1000 mg/day, split across meals.
    • Phosphatidylserine 100-300 mg/day — another membrane phospholipid component.
    • Phosphatidylcholine — additional choline source, often from lecithin.
    • Acetyl-L-carnitine 500-1500 mg/day — supports mitochondrial fatty acid oxidation, some cognitive evidence.

    Comprehensive brain-health stack (illustrative, each component independently considered):

    • Uridine monophosphate 1500-2000 mg/day
    • Alpha-GPC 900 mg/day + phosphatidylcholine 500 mg/day
    • DHA 2000 mg/day + EPA 1000 mg/day
    • Phosphatidylserine 200 mg/day
    • Acetyl-L-carnitine 1000 mg/day
    • Nicotinamide Riboside or NMN 250-500 mg/day
    • Creatine 5 g/day
    • Magnesium L-threonate 1-2 g/day (proposed CNS-preferential magnesium)
    • Lion's Mane 1-2 g/day
    • B-complex + additional methylfolate and methylcobalamin for methylation support
    • Vitamin D3 3000-5000 IU
    • Vitamin K2 (MK-7) 100-200 mcg
    • Vitamin E (mixed tocopherols) 100-200 IU
    • Selenium 100-200 mcg
    • Zinc 10-25 mg (balanced with copper 1-2 mg)
    • Comprehensive Mediterranean-style diet with emphasis on polyphenols
    • Daily aerobic and resistance exercise
    • Cognitive engagement (reading, learning, creative work)
    • Social engagement
    • Sleep optimisation (7-9 hours, consistent schedule)

    Advanced monitoring:

    • Annual comprehensive labs: CBC, CMP, lipid panel, HbA1c, fasting insulin, TSH, free T4, free T3, vitamin D, B12, folate, homocysteine, hs-CRP, ferritin, iron studies, uric acid, magnesium, zinc, copper.
    • Every 2-3 years (if indicated by age or risk factors): consider cognitive screening (MoCA or similar), cardiovascular assessment.
    • If age 50+ or family history of Alzheimer's: consider discussing genetic testing (APOE4 status), brain imaging (MRI), and CSF/blood biomarker testing with a neurologist.
    • Regular primary care and age-appropriate screening.

    Risks of the advanced approach:

    • Polypharmacy — even with individually benign supplements, comprehensive stacks increase interaction risk and complexity.
    • Financial cost — comprehensive stack can be $200-400/month.
    • Opportunity cost — attention to supplement optimisation can distract from higher-impact interventions (exercise, sleep, social connection, career engagement).
    • Diminishing returns — beyond a foundational level of nutrition and basic supplementation, additional components may add little.
    • Missed pathology — relying on supplements to "preserve cognition" may mask early warning signs that require medical evaluation (depression, sleep apnoea, thyroid disease, vascular disease).

    The exit strategy:

    • Every 6-12 months, systematically evaluate each component: what evidence supports it? What is the marginal benefit? Would removing it produce noticeable effects?
    • Aim for the simplest stack producing the desired result.
    • Foundational interventions (sleep, exercise, nutrition, stress management, social engagement, cognitive engagement) produce larger effects than any supplement stack; ensure they are optimised before investing heavily in supplements.

    Honest advanced assessment: if you are at 2000 mg/day uridine with a 15-component stack and still concerned about cognitive function, the answer is probably not "more supplements." Consider: formal cognitive assessment, evaluation for sleep disorders, comprehensive medical evaluation, review of medications (many prescription medications have cognitive side effects), evaluation of alcohol use, and review of lifestyle factors. Uridine is a modest contributor to cognitive support; it is not a solution for meaningful cognitive concerns.

    For users with genuine Alzheimer's-spectrum concerns:

    • Neurologist or cognitive specialist evaluation is essential.
    • Approved therapies (cholinesterase inhibitors, memantine, and for appropriate patients, lecanemab or donanemab) have substantially stronger evidence than Souvenaid/uridine-based medical foods.
    • Souvenaid may have adjunctive role in early disease under physician guidance.
    • Lifestyle interventions (Mediterranean diet, aerobic exercise, cognitive engagement, social engagement) have among the strongest evidence for delaying cognitive decline.

    Commonly Stacked With

    Uridine monophosphate is one of the most commonly stacked nootropic supplements because of its clear mechanistic synergy with choline and omega-3 fatty acids for membrane phospholipid synthesis. The evidence for specific combinations ranges from mechanism-based (strong) to purely anecdotal (weak).

    The "Mr. Happy Stack" and variants (uridine + choline + DHA). The canonical nootropic stack based on uridine's mechanism:

    • Uridine monophosphate 150-250 mg sublingual or 250-500 mg oral once or twice daily.
    • Choline source: alpha-GPC 300-600 mg/day OR CDP-choline 250-500 mg/day.
    • DHA (docosahexaenoic acid) 700-1400 mg/day — can be from fish oil, krill oil, or algal oil. EPA is often included; ratios of 2:1 or higher DHA:EPA are preferred for neurological applications.

    This stack is based on the Wurtman group's work and has the strongest mechanistic rationale of any community nootropic combination. It is also the formulation used in Souvenaid (with additional components). Users typically report effects that accumulate over 2-8 weeks — subtle but sustained improvements in mood, mental clarity, and cognitive function. This is the recommended "first stack" for users interested in long-term membrane-supporting nootropics.

    Uridine + noopept. A popular community combination. Noopept has proposed BDNF/NGF effects and AMPA modulation; uridine supports membrane substrate availability. Anecdotal synergy but no trial data. Adding a choline source is typical.

    Uridine + piracetam or other racetams. Racetams are thought to have cholinergic effects; uridine supports the substrate pathway for cholinergic membrane components. Classic "basic nootropic stack" combination, often with a choline source added.

    Uridine + lions-mane. Lion's Mane contains hericenones and erinacines proposed to stimulate NGF; uridine supports membrane substrate. Mechanistically complementary, though both operate on longer timescales (weeks-to-months) rather than acute effects.

    Uridine + nad or NAD precursors. NAD supports mitochondrial function; uridine supports membrane synthesis. Complementary pathways. Community combination without specific trial data.

    Uridine + sulbutiamine. Sulbutiamine provides enhanced CNS thiamine; uridine supports membrane synthesis. Reasonable combination, particularly for fatigue-plus-cognitive-complaint presentations.

    Uridine + selank or semax. Russian peptide nootropics with claimed BDNF/neurotrophic effects; uridine supports membrane substrate. Community combination.

    Uridine + modafinil. Modafinil provides acute wakefulness; uridine provides long-term membrane support. Different timescales but can coexist.

    Uridine + l-theanine + caffeine. Simple combination — caffeine for acute alertness, theanine for smoothness, uridine for long-term membrane support. Low-risk, commonly used.

    Uridine + creatine monohydrate. Creatine supports cellular energy via phosphocreatine buffering; uridine supports membrane synthesis. Excellent general "brain health" combination with very safe profile.

    Uridine + omega-3 fatty acids alone. A common simpler version of the Mr. Happy Stack without the choline component. Still beneficial for membrane support but less complete.

    What NOT to combine uridine with:

    • Pyrimidine antagonist chemotherapy (5-FU, capecitabine, cytarabine): potentially antagonistic. Avoid unless directed by oncologist.
    • Multiple novel nootropics simultaneously on first trial — though uridine's low side-effect profile makes this less concerning than with more active compounds, isolated assessment is still preferable.

    Prescription medication considerations. Uridine is unlikely to produce clinically significant interactions with common psychiatric, cardiovascular, or general medications. Users on any medication should still inform their prescribing physician about all supplements. Specific caution with pyrimidine antagonist chemotherapy (as above).

    Lifestyle co-factors. Uridine's mechanism depends on adequate substrate availability more broadly. Users benefit from:

    • Adequate choline intake — dietary (eggs, liver, fish, dairy) and/or supplemental.
    • Adequate omega-3 intake — dietary (fatty fish) and/or supplemental.
    • Adequate B-vitamin status — particularly folate, B6, B12 for methylation and one-carbon metabolism.
    • Adequate protein — for general amino acid and cofactor availability.
    • Exercise — which independently promotes BDNF, neurogenesis, and cognitive health.
    • Sleep — during which significant synaptic remodeling and memory consolidation occur.

    Uridine without these lifestyle factors is operating in a suboptimal environment; with them, it may provide additional membrane-synthesis support.

    Timing recommendations for stacks:

    • Morning and/or midday — uridine is neither particularly activating nor sedating, but most stacks are taken earlier in the day.
    • With food — particularly with fat-containing meals to support DHA absorption and to reduce any mild GI effects.
    • Consistent daily dosing — effects are cumulative rather than acute; missing occasional doses doesn't matter much but consistency over weeks-to-months is what produces the full benefit profile.

    Side Effects & Safety

    Uridine monophosphate has one of the most favourable safety profiles of any supplement in the nootropic space. It is a naturally occurring nutrient, present in human breast milk, liver, fish, and many other foods. Clinical trials with daily doses up to 2 grams have shown good tolerability. **Common side effects (reported in ≥1-5% of users, generally mild):** - **Mild GI upset** — occasional nausea, loose stools, or abdominal discomfort. Usually resolves with dose adjustment or taking with food. - **Headache** — rare but occasionally reported, particularly at higher doses or in combination with other supplements. - **Mood changes** — most users report no mood effect or slight improvement; a minority report irritability or low mood. - **Fatigue** — paradoxical tiredness in some users, typically transient. **Less common side effects:** - **Sleep changes** — uridine doesn't typically disrupt sleep, but some users report changes in sleep architecture or dream recall when starting supplementation. - **Hyperuricemia and gout** — a theoretical concern because uridine is a pyrimidine nucleotide and its metabolism can produce some uric acid. In clinical studies, supplemental uridine at typical doses has NOT been shown to cause clinically significant hyperuricemia. However, patients with existing gout or hyperuricemia should monitor uric acid levels if starting uridine. - **Taste/organoleptic complaints** — uridine powder has a slightly bitter taste; encapsulation or mixing with food generally addresses this. **Rarely reported:** - **Allergic reactions** — rash, urticaria. Uncommon. Discontinue if severe. - **Pancreatic effects** — pyrimidine nucleotides participate in pancreatic function; case reports exist of uridine-related pancreatic issues but are not a clear safety signal at typical doses. **Long-term safety:** - Uridine has been used in Souvenaid and related medical foods over trials of 24 months without significant adverse signals beyond mild GI effects. - No evidence of organ toxicity at typical supplemental doses. - No evidence of dependency, tolerance, or withdrawal on discontinuation. **Specific considerations:** - **Gout and hyperuricemia.** Individuals with a history of gout, elevated baseline uric acid, or kidney stones should monitor uric acid levels when starting uridine. Theoretical concern because nucleotide metabolism contributes to the uric acid pool; in practice, effects are generally minor at typical doses. - **Pregnancy and lactation.** Uridine is a natural component of breast milk and a normal dietary constituent; supplemental doses at typical levels are unlikely to cause harm but have not been specifically tested for safety in pregnancy. Discuss with obstetrician before starting if pregnant. - **Paediatric use.** Uridine monophosphate has been included in some infant formulas to mimic breast milk composition and has been used in paediatric medical foods for specific indications under medical supervision. Self-administration in healthy children is not typical practice but is unlikely to cause harm at typical doses. - **Kidney disease.** Uridine is primarily metabolised rather than renally excreted, but caution in severe renal impairment is reasonable. - **Liver disease.** Uridine undergoes hepatic metabolism; caution in severe hepatic impairment is reasonable though no specific adverse signals have been identified. - **Cancer.** Theoretical concerns have been raised about pyrimidine nucleotides potentially supporting cancer cell growth (rapidly dividing cells need nucleotides). However, uridine is a dietary component and is not classified as cancer-promoting. Patients actively undergoing cancer treatment — particularly with pyrimidine antagonist chemotherapy (5-fluorouracil, capecitabine, cytarabine) — should discuss uridine supplementation with their oncologist, as exogenous uridine could theoretically antagonise treatment efficacy. In fact, uridine triacetate (Vistogard) is an FDA-approved antidote for 5-fluorouracil overdose specifically because uridine competes with 5-FU metabolism. - **Diabetes.** Uridine-diphosphate-glucose (UDP-glucose) is involved in glucose handling. No clear clinical evidence of glucose effects at typical supplemental doses. **Drug interactions:** - **Pyrimidine antagonist chemotherapy (5-FU, capecitabine, cytarabine, floxuridine):** uridine may antagonise the therapeutic effect of these drugs. In fact, uridine triacetate is approved as an antidote for 5-FU overdose. Do not combine uridine supplementation with these chemotherapy agents without oncologist guidance. - **Allopurinol and xanthine oxidase inhibitors:** no specific interaction documented, but if using uridine in the context of gout, coordinate with prescribing physician. - **General psychiatric and cognitive medications:** no specific documented adverse interactions. Uridine does not meaningfully inhibit or induce CYP450 enzymes. - **General cardiovascular medications:** no specific documented interactions. **Quality and product considerations:** - **Uridine monophosphate disodium salt (UMP-Na2)** is the most common supplemental form — good oral bioavailability and stability. - **Triacetyl uridine (TAU)** is a lipid-soluble form with claimed better bioavailability; more expensive and less commonly used. - **Free uridine** (the nucleoside without phosphate) has lower effective oral bioavailability for raising brain uridine compared with UMP. - Avoid products without clear source documentation; look for third-party testing where possible. **When to stop and seek medical attention:** - Allergic reaction (rash, hives, difficulty breathing). - Severe or persistent GI symptoms. - Significant mood deterioration. - Signs of acute gout flare (if predisposed). - Any symptom you would take seriously on a prescription medication.

    Contraindications

    **Absolute contraindications:** - **Active pyrimidine antagonist chemotherapy** — patients receiving 5-fluorouracil (5-FU), capecitabine (Xeloda), cytarabine (Ara-C), floxuridine, tegafur, or related pyrimidine antagonist drugs should NOT supplement with uridine. Exogenous uridine antagonises these drugs' therapeutic effect. In fact, uridine triacetate (Vistogard) is FDA-approved specifically as an antidote for 5-FU overdose. - **Known hypersensitivity** to uridine, UMP, or any component of the supplement formulation. **Relative contraindications (discuss with physician before use):** - **History of gout or hyperuricemia.** Uridine metabolism contributes modestly to the uric acid pool. While clinical impact is usually minor, patients with active gout, history of gout, or significantly elevated baseline uric acid should monitor uric acid when starting uridine. Consider coordination with rheumatologist or primary care. - **Kidney stones (uric acid type).** Similar concern. Monitor. - **Severe hepatic impairment.** Uridine undergoes hepatic metabolism; caution in severe liver dysfunction, though specific safety data are limited. - **Severe renal impairment.** Generally well tolerated but no specific studies in severe renal failure. - **Active cancer.** While supplemental uridine is not considered cancer-promoting, and dietary uridine is a normal constituent of human nutrition, patients with active cancer should discuss all supplements with their oncology team. Specific concerns with pyrimidine antagonist chemotherapy (as above). - **Bipolar disorder.** Uridine has been studied as an adjunct in bipolar depression with potential benefit, but should only be used under psychiatric supervision in this context. Not appropriate for self-administration in active mood episodes. **Pregnancy and lactation:** - **Pregnancy:** uridine is a natural dietary constituent and component of breast milk. Supplemental doses are unlikely to cause harm but have not been specifically tested for safety in pregnancy. Discuss with obstetrician before starting or continuing any supplement in pregnancy. - **Lactation:** uridine is naturally present in breast milk at meaningful concentrations. Supplemental uridine by lactating mothers is unlikely to cause harm. Discuss with paediatrician or obstetrician if concerned. **Paediatric use:** - Uridine is a normal component of infant nutrition (breast milk, some infant formulas). - Uridine-containing medical foods have been used in paediatric patients under medical supervision for specific indications. - Self-administration of supplemental uridine in healthy children is not typical practice and is not recommended without medical indication. **Drug class interactions:** - **Pyrimidine antagonist chemotherapy:** ABSOLUTE avoidance (as above). - **Allopurinol, febuxostat (xanthine oxidase inhibitors):** no direct interaction documented; if using for gout management, coordinate uridine supplementation with prescribing physician. - **Psychiatric medications (SSRIs, SNRIs, MAOIs, tricyclics, antipsychotics, mood stabilisers, stimulants):** no documented clinically significant interactions. Uridine does not meaningfully inhibit or induce CYP450 enzymes. - **Anticoagulants (warfarin, DOACs):** no documented interaction. - **Antidiabetic agents:** no documented interaction. - **Cardiovascular medications (antihypertensives, statins, antiplatelets):** no documented interaction. - **Immunosuppressants:** no documented interaction. - **General supplements (choline, DHA, B-vitamins, magnesium, etc.):** synergistic with mechanistically related supplements; no adverse interactions documented. **Athlete considerations:** - Uridine is NOT on the WADA Prohibited List. - It is a natural dietary constituent and not considered a performance-improving substance in athletic contexts. - Athletes can use uridine without anti-doping concerns. **Travel considerations:** - Uridine is an over-the-counter supplement in most jurisdictions. - Some jurisdictions may regulate supplements differently; generally not a problem for personal use quantities. **Regulatory status:** - **United States:** uridine monophosphate is sold as a dietary supplement under DSHEA. Not FDA-approved as a drug. - **European Union:** present in medical foods (Souvenaid) with specific regulated indications. Also available as supplement. - **Other jurisdictions:** generally available as supplement; regulation varies. **When to stop and seek medical attention:** - Signs of allergic reaction (rash, swelling, difficulty breathing). - Severe or persistent GI symptoms. - Signs of acute gout flare (if predisposed). - Significant unexplained mood deterioration. - Any symptom you would take seriously on a prescription medication. **Situations to seek medical evaluation BEFORE starting uridine:** - Unexplained cognitive complaints (warrant formal evaluation, not self-treatment). - Significant depression or anxiety (warrant formal psychiatric evaluation). - Known or suspected cancer. - Any acute or rapidly changing medical condition. - Use in children. **The bottom line:** uridine monophosphate is one of the safer supplements in the nootropic space, with a favourable risk-benefit profile for most healthy adults interested in general cognitive support and membrane health. It has modest but legitimate evidence for specific applications (prodromal/mild Alzheimer's via Souvenaid, adjunct in bipolar depression) and is generally well tolerated at typical supplemental doses. It is not a substitute for evidence-based evaluation and treatment of genuine cognitive, mood, or medical concerns.

    Check interactions with the Interaction Checker →

    Additional Notes

    Uridine monophosphate dosing summary:

    • Starter dose: 150-250 mg daily.
    • Intermediate dose: 500-1000 mg daily.
    • Advanced/long-term dose: up to 1500-2000 mg daily.
    • Clinical trial doses (e.g., bipolar depression studies): 500-1000 mg twice daily.
    • Souvenaid medical food: contains approximately 625 mg UMP per daily serving as part of combined formulation.

    Timing:

    • Take with food — particularly with meals containing some fat, as this supports DHA co-administration and reduces mild GI effects.
    • Morning and/or midday dosing is typical. Uridine is not notably activating or sedating, so timing is flexible.
    • Consistent daily dosing — benefits are cumulative over weeks; consistency matters more than precise daily timing.
    • Split dosing for higher daily amounts (>500 mg) — typical split is with breakfast and dinner.

    Administration routes:

    • Oral — standard route. Swallow whole with water. Absorption is reasonable, though first-pass metabolism reduces bioavailability to some extent.
    • Sublingual — a subset of users prefer sublingual administration (dissolving tablet or powder under tongue for 1-2 minutes) for faster onset and potentially better bioavailability of the small molecule. Sublingual tablets are specifically marketed for this purpose.
    • Avoid: intranasal and injectable uridine — not established routes; no safety data.

    Forms and bioavailability:

    • Uridine monophosphate disodium salt (UMP-Na2): most common supplemental form. Good oral bioavailability. Water-soluble.
    • Triacetyluridine (TAU or TUU): lipid-soluble prodrug form with claimed superior bioavailability. More expensive, less commonly used.
    • Free uridine (the nucleoside): less commonly used supplemental form; lower effective bioavailability compared with UMP.
    • Food sources: dietary uridine from liver, fish, broccoli, beer yeast, breast milk provides background nucleotide supply but quantitatively small compared with supplemental doses.

    Pharmacokinetics:

    • Oral absorption: reasonable; varies with form.
    • Peak plasma uridine: 1-2 hours post-dose.
    • Half-life: approximately 2-4 hours for exogenous plasma uridine.
    • CNS uptake: via saturable nucleoside transporters (ENT, CNT).
    • Metabolism: intracellular phosphorylation to UMP → UDP → UTP → CTP; excess catabolised via uridine phosphorylase.

    With food considerations:

    • Fat-containing meals enhance absorption of co-administered DHA.
    • Food reduces mild GI upset.
    • Heavily processed foods or high-sugar meals don't specifically interfere but aren't optimal for any nootropic stack.

    Cycling considerations:

    • Uridine does NOT require cycling — it is a nutritional precursor without tolerance development.
    • Most users dose continuously for months to years without dose escalation or cycling.
    • Periodic breaks are harmless but unnecessary.

    Missed dose:

    • If within 4-6 hours of scheduled time: take when remembered.
    • If later in the day: skip and resume next day. Do not double-dose.
    • Missing occasional doses has minimal impact on cumulative benefits.

    Overdose:

    • Uridine has a wide safety margin. Doses up to 2 g/day have been used in trials without significant adverse events beyond mild GI effects.
    • Very high doses (several grams) might produce more pronounced GI effects and possibly transient hyperuricemia in predisposed individuals.
    • No reports of clinically significant acute uridine toxicity in humans.
    • If excessive ingestion occurs with concerning symptoms, contact poison control.

    Special populations:

    • Elderly: uridine is commonly recommended/used for age-related cognitive support. Start with lower doses (150-250 mg/day) and titrate if desired. Monitor for gout if predisposed.
    • Pregnancy: uridine is a natural dietary constituent and component of breast milk. Supplemental doses are unlikely to cause harm but have not been specifically tested for safety. Discuss with obstetrician.
    • Lactation: uridine is naturally present in breast milk. Supplemental uridine by lactating mothers is unlikely to cause harm but has not been specifically studied.
    • Paediatric use: uridine is a component of some infant formulas designed to mimic breast milk. Has been used in paediatric medical foods under supervision. Not typically supplemented in healthy children.
    • Gout or hyperuricemia: monitor uric acid if starting uridine. Clinical impact is typically minimal but worth checking.
    • Hepatic impairment: hepatic metabolism contributes to uridine handling; caution in severe hepatic dysfunction.
    • Renal impairment: minimal primary renal excretion at supplemental doses; generally well tolerated.
    • Cancer on pyrimidine antagonist chemotherapy: uridine may antagonise the therapeutic effect of 5-FU, capecitabine, and related agents. Avoid unless directed by oncologist.
    • Diabetes: no specific concerns at typical doses.
    • Cardiovascular disease: no specific contraindication.

    Frequently Asked Questions

    What is the recommended Uridine Monophosphate (UMP) dosage?

    Dosage for Uridine Monophosphate (UMP) varies by protocol. Consult a qualified healthcare provider.

    How often should I take Uridine Monophosphate (UMP)?

    Administration frequency depends on the specific protocol. Consult current research literature.

    Does Uridine Monophosphate (UMP) need to be cycled?

    Cycling requirements depend on the protocol. Follow established research guidelines.

    What are Uridine Monophosphate (UMP) side effects?

    Uridine monophosphate has one of the most favourable safety profiles of any supplement in the nootropic space. It is a naturally occurring nutrient, present in human breast milk, liver, fish, and many other foods. Clinical trials with daily doses up to 2 grams have shown good tolerability. **Common side effects (reported in ≥1-5% of users, generally mild):** - **Mild GI upset** — occasional nausea, loose stools, or abdominal discomfort. Usually resolves with dose adjustment or taking with food. - **Headache** — rare but occasionally reported, particularly at higher doses or in combination with other supplements. - **Mood changes** — most users report no mood effect or slight improvement; a minority report irritability or low mood. - **Fatigue** — paradoxical tiredness in some users, typically transient. **Less common side effects:** - **Sleep changes** — uridine doesn't typically disrupt sleep, but some users report changes in sleep architecture or dream recall when starting supplementation. - **Hyperuricemia and gout** — a theoretical concern because uridine is a pyrimidine nucleotide and its metabolism can produce some uric acid. In clinical studies, supplemental uridine at typical doses has NOT been shown to cause clinically significant hyperuricemia. However, patients with existing gout or hyperuricemia should monitor uric acid levels if starting uridine. - **Taste/organoleptic complaints** — uridine powder has a slightly bitter taste; encapsulation or mixing with food generally addresses this. **Rarely reported:** - **Allergic reactions** — rash, urticaria. Uncommon. Discontinue if severe. - **Pancreatic effects** — pyrimidine nucleotides participate in pancreatic function; case reports exist of uridine-related pancreatic issues but are not a clear safety signal at typical doses. **Long-term safety:** - Uridine has been used in Souvenaid and related medical foods over trials of 24 months without significant adverse signals beyond mild GI effects. - No evidence of organ toxicity at typical supplemental doses. - No evidence of dependency, tolerance, or withdrawal on discontinuation. **Specific considerations:** - **Gout and hyperuricemia.** Individuals with a history of gout, elevated baseline uric acid, or kidney stones should monitor uric acid levels when starting uridine. Theoretical concern because nucleotide metabolism contributes to the uric acid pool; in practice, effects are generally minor at typical doses. - **Pregnancy and lactation.** Uridine is a natural component of breast milk and a normal dietary constituent; supplemental doses at typical levels are unlikely to cause harm but have not been specifically tested for safety in pregnancy. Discuss with obstetrician before starting if pregnant. - **Paediatric use.** Uridine monophosphate has been included in some infant formulas to mimic breast milk composition and has been used in paediatric medical foods for specific indications under medical supervision. Self-administration in healthy children is not typical practice but is unlikely to cause harm at typical doses. - **Kidney disease.** Uridine is primarily metabolised rather than renally excreted, but caution in severe renal impairment is reasonable. - **Liver disease.** Uridine undergoes hepatic metabolism; caution in severe hepatic impairment is reasonable though no specific adverse signals have been identified. - **Cancer.** Theoretical concerns have been raised about pyrimidine nucleotides potentially supporting cancer cell growth (rapidly dividing cells need nucleotides). However, uridine is a dietary component and is not classified as cancer-promoting. Patients actively undergoing cancer treatment — particularly with pyrimidine antagonist chemotherapy (5-fluorouracil, capecitabine, cytarabine) — should discuss uridine supplementation with their oncologist, as exogenous uridine could theoretically antagonise treatment efficacy. In fact, uridine triacetate (Vistogard) is an FDA-approved antidote for 5-fluorouracil overdose specifically because uridine competes with 5-FU metabolism. - **Diabetes.** Uridine-diphosphate-glucose (UDP-glucose) is involved in glucose handling. No clear clinical evidence of glucose effects at typical supplemental doses. **Drug interactions:** - **Pyrimidine antagonist chemotherapy (5-FU, capecitabine, cytarabine, floxuridine):** uridine may antagonise the therapeutic effect of these drugs. In fact, uridine triacetate is approved as an antidote for 5-FU overdose. Do not combine uridine supplementation with these chemotherapy agents without oncologist guidance. - **Allopurinol and xanthine oxidase inhibitors:** no specific interaction documented, but if using uridine in the context of gout, coordinate with prescribing physician. - **General psychiatric and cognitive medications:** no specific documented adverse interactions. Uridine does not meaningfully inhibit or induce CYP450 enzymes. - **General cardiovascular medications:** no specific documented interactions. **Quality and product considerations:** - **Uridine monophosphate disodium salt (UMP-Na2)** is the most common supplemental form — good oral bioavailability and stability. - **Triacetyl uridine (TAU)** is a lipid-soluble form with claimed better bioavailability; more expensive and less commonly used. - **Free uridine** (the nucleoside without phosphate) has lower effective oral bioavailability for raising brain uridine compared with UMP. - Avoid products without clear source documentation; look for third-party testing where possible. **When to stop and seek medical attention:** - Allergic reaction (rash, hives, difficulty breathing). - Severe or persistent GI symptoms. - Significant mood deterioration. - Signs of acute gout flare (if predisposed). - Any symptom you would take seriously on a prescription medication.

    Where can I buy Uridine Monophosphate (UMP)?

    Visit our vendor directory to find trusted sources for Uridine Monophosphate (UMP).

    Free 2026 Peptide Cheat Sheet — 50 pages, PDF

    Dosing, reconstitution, stacks, half-lives, and vendor trust tiers. The reference we wish we had on day one.

    Download Free